2084-LB: Real-World Effectiveness of Tirzepatide among People with Obesity or Overweight without Type 2 Diabetes (T2D)

• Published in: Diabetes (New York, N.Y.) Vol. 73; p. 1
• Main Authors: Hankosky, Emily R, Desai, Karishma, Chinthammit, Chanadda, Grabner, Michael, Stockbower, Grace, He, Xuanyao, Mojdami, Donna, Wenziger, Cachet, Gibble, Theresa Hunter
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2024
• Subjects: Antidiabetics; Body weight; Body weight loss; Comorbidity; Diabetes; Diabetes mellitus (non-insulin dependent); Dyslipidemia; Obesity; Overweight; Patients; Weight control

Introduction & Objective: Tirzepatide is a once weekly GIP and GLP-1 receptor agonist approved in the US for treatment of T2D (May 2022) and obesity (Nov 2023). We assessed real-world patient characteristics and effectiveness in people with obesity or overweight without T2D. Methods: This retros...